Brodalumab in the Treatment of Immune-Related Adverse Events
NCT06673329
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Esophageal Cancer
- Kidney Cancer
- Lung Cancer
- Thyroid Cancer
- Gynecologic Cancer
- Pancreatic Cancer
- Stomach Cancer
- Brain Tumor
- Colon Cancer
- Rectal Cancer
- Head and Neck Cancer
- Oral Cancer
- Liver Cancer
- Skin Cancer
- Prostate Cancer
- Testicular Cancer
- Solid Tumor
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Brian Henick, MD
- Last updated on ClinicalTrials.gov
- May 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Columbia University Irving Medical Center · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.